A recent Nordic research study has shed light on the potential increased risk of stillbirth among pregnant women infected with COVID-19. This comprehensive study, the largest of its kind, analysed data from 389,949 births across Norway, Sweden and Denmark. The findings revealed a 2.4 times higher risk of stillbirth among women who contracted COVID-19 during pregnancy.
While stillbirth remains a rare occurrence, the study found that the absolute risk was 2.3 per 100,000 follow-up days for pregnant women without COVID-19. In contrast, the risk was 5.8 per 100,000 follow-up days for those who contracted the virus during pregnancy. Notably, the risk of stillbirth was highest within the first two weeks of infection.
The study also discovered that the risk of stillbirth varied based on the COVID-19 variant that the pregnant woman tested positive for. The risk was highest during the period when the Delta variant was dominant. However, due to changes in COVID-19 testing recommendations, the risk associated with current variants remains unknown.
In light of these findings, the Norwegian Institute of Public Health recommends pregnant women get vaccinated against COVID-19 during their second or third trimester. This recommendation is based on research showing a certain increased risk of serious illness or complications among pregnant women infected by COVID-19, with no connected risk for the mother, child, or pregnancy among those vaccinated.
🚀 Discover the critical role of policy in advancing #AI in medical diagnostics and how it can transform patient care. Read our latest article to understand the intersection of innovative technology and healthcare policy. #HealthcareInnovation #MedicalDiagnostics #ArtificialIntelligence
Discover how #BiosimilarCompetition influences patient costs in the #HealthcareIndustry. A recent analysis unpacks the complexities of #BiologicMedications and their impact on out-of-pocket expenses. 📊💊
Are patients truly saving money with biosimilars? Find out in our latest article. #LifeSciencesConsulting #PharmaMarketAccess #ValueBasedHealthcare
Read more and join the discussion on how we can make life-saving treatments more affordable. #PatientAffordability #HealthcareCosts
🌍 Access to affordable medicines remains a critical global challenge. 🏥Discover how we are slowing shaping a future where healthcare equity is a reality for all. #HealthcareInnovation #AccessToMedicines #GlobalHealth 🌍💊
Despite advancements in technology and innovation, millions remain excluded from essential treatments. We explore various methods to expand access to medications, focusing on evidence-based policies, innovative strategies, and the power of collaboration.
Key takeaways include the role of evidence and transparency in achieving ‘fair prices’, the need for innovative policy reform, and the importance of multi-sectoral collaboration for sustainable access to affordable medications. 🤝💪🏽
#PharmaceuticalPolicy #Collaboration #HealthEquity 🌍🩺💊
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
